Nuclear Medicine and Biology
Volume 33, Issue 3 , Pages 371-380 , April 2006

Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma

Received 9 October 2005 ,Revised 30 November 2005 ,Accepted 4 December 2005.

References 

  1. Jemal A, Ward E, Thun MJ. Contemporary lung cancer trends among U.S. women. Cancer Epidemiol Biomarkers Prev. 2005;14:582–585
  2. Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am. 2003;30:219–226
  3. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol. 1999;26:407–421
  4. Sunday ME, Wolfe HJ, Roos BA, Chin WW, Spindel ER. Gastrin-releasing peptide gene expression in developing, hyperplastic, and neoplastic human thyroid C-cells. Endocrinology. 1988;122:1551–1558
  5. Guo YS, Townsend CM. Roles of gastrointestinal hormones in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2000;7:276–285
  6. Scott N, Millward E, Cartwright EJ, Preston SR, Coletta PL. Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours. J Clin Pathol. 2004;57:189–192
  7. Glover SC, Tretiakova MS, Carroll RE, Benya RV. Increased frequency of gastrin-releasing peptide receptor gene mutations during colon-adenocarcinoma progression. Mol Carcinog. 2003;37:5–15
  8. Scopinaro F, Varvarigou AD, Ussof W, De Vincentis G, Sourlingas TG, Evangelatos GP, et al. Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother Radiopharm. 2002;17:327–335
  9. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 2000;42:295–303
  10. Williams BY, Schonbrunn A. Bombesin receptors in a human duodenal tumor cell line: binding properties and function. Cancer Res. 1994;54:818–824
  11. Chung DH, Evers BM, Beauchamp RD, Upp JR, Rajaraman S, Townsend CM, et al. Bombesin stimulates growth of human gastrinoma. Surgery. 1992;112:1059–1065
  12. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer. 1989;63:1714–1720
  13. Aprikian AG, Han K, Guy L, Landry F, Begin LR, Chevalier S. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate Suppl. 1998;8:52–61
  14. Jongsma J, Oomen MH, Noordzij MA, Romijn JC, van Der Kwast TH, Schroder FH, et al. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate. 2000;42:34–44
  15. Koppan M, Halmos G, Arencibia JM, Lamharzi N, Schally AV. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer. 1998;83:1335–1343
  16. Szepeshazi K, Halmos G, Schally AV, Arencibia JM, Groot K, Vadillo-Buenfil M, et al. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J Cancer Res Clin Oncol. 1999;125:444–452
  17. Zhou J, Chen J, Mokotoff M, Ball ED. Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs. 2004;15:921–927
  18. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab. 2004;15:300–310
  19. Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol. 2003;30:861–868
  20. Scheffel U, Pomper MG. PET imaging of GRP receptor expression in prostate cancer. J Nucl Med. 2004;45:1277–1278
  21. Varvarigou A, Bouziotis P, Zikos C, Scopinaro F, De Vincentis G. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother Radiopharm. 2004;19:219–229
  22. Van de Wiele C, Dumont F, van Belle S, Slegers G, Peers SH, Dierckx RA. Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging?. Nucl Med Commun. 2001;22:5–15
  23. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M, et al. Peptide receptor radionuclide therapy. Ann N Y Acad Sci. 2004;1014:234–235
  24. Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(Suppl 1):172S–178S
  25. Van de Wiele C, Dumont F, Dierckx RA, Peers SH, Thornback JR, Slegers G, et al. Biodistribution and dosimetry of 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42:1722–1727
  26. Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694–1699
  27. Shao Y, Cherry SR, Farahani K, Meadors K, Siegel S, Silverman RW, et al. Simultaneous PET and MR imaging. Phys Med Biol. 1997;42:1965–1970
  28. Schuhmacher J, Zhang H, Doll J, Macke HR, Matys R, Hauser H, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med. 2005;46:691–699
  29. Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, et al. MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45:1390–1397
  30. Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14:756–763
  31. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35–43
  32. Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, et al. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res. 1999;5:3608–3616
  33. Rogers BE, Manna DD, Safavy A, et al. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate. Cancer Biother Radiopharm. 2004;19:25–34
  34. Yaghoubi S, Barrio JR, Dahlbom M, Iyer M, Namavari M, Satyamurthy N, et al. Human pharmacokinetic and dosimetry studies of [18F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med. 2001;42:1225–1234
  35. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274–292
  36. Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173:252–255
  37. Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32:742–748
  38. Seltzer MA, Jahan SA, Sparks R, Stout DB, Satyamurthy N, Dahlbom M, et al. Radiation dose estimates in humans for 11C-acetate whole-body PET. J Nucl Med. 2004;45:1233–1236
  39. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465–1474
  40. Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, et al. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res. 2004;10:8674–8682
  41. Wong EH, Weisman GR, Hill DC, Reed DP, Rogers ME, Condon JS, et al. Synthesis and characterization of cross-bridged cyclams and pendant-armed derivatives and structural studies of their copper(II) complexes. J Am Chem Soc. 2000;122:10561–10572
  42. Sun X, Wuest M, Weisman GR, Wong EH, Reed DP, Boswell CA, et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem. 2002;45:469–477

PII: S0969-8051(05)00295-7

doi: 10.1016/j.nucmedbio.2005.12.011

Nuclear Medicine and Biology
Volume 33, Issue 3 , Pages 371-380 , April 2006

Article Tools

* Image Usage & Resolution